Guggenheim raised the firm’s price target on Exelixis to $30 from $27 and keeps a Buy rating on the shares. After positive top-line PFS results for the CONTACT-02 study of Cabometyx + atezolizumab in mCRPC were reported last month, the firm spoke with two key opinion leader prostate cancer physicians on the study and overall market opportunity for Cabo and is updating its mCRPC market model and assumptions for probability-adjusted sales for the combo in first and second line mCRPC beginning in 2025, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
- Exelixis in $80M deal with Insilico for global rights to develop ISM3091
- Exelixis announces DSMB recommendation to unblind CABINET trial
- Exelixis appoints Amy Peteson as Chief Medical Officer
- Exelixis price target raised to $27 from $24 at JMP Securities
- Exelixis, Ipsen announce CONTACT-02 trial met one of two primary endpoints
